- Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
- Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
- Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
- Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
- Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
- Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
- Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
- Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
- Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
More ▼
Key statistics
On Tuesday, Oncolytics Biotech Inc (ONC:TOR) closed at 1.43, 19.17% above the 52 week low of 1.20 set on Feb 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.45 |
---|---|
High | 1.47 |
Low | 1.42 |
Bid | 1.43 |
Offer | 1.49 |
Previous close | 1.44 |
Average volume | 26.46k |
---|---|
Shares outstanding | 75.42m |
Free float | 72.48m |
P/E (TTM) | -- |
Market cap | 110.11m CAD |
EPS (TTM) | -0.4027 CAD |
Data delayed at least 15 minutes, as of Jun 04 2024 20:59 BST.
More ▼